Selected research
Market Structure
Global Benign Prostatic Hypertrophy Medication Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Benign Prostatic Hypertrophy Medication market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Benign Prostatic Hypertrophy Medication is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Benign Prostatic Hypertrophy Medication is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Benign Prostatic Hypertrophy Medication is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Benign Prostatic Hypertrophy Medication is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Benign Prostatic Hypertrophy Medication include Abbott Laboratories, Allergan, Inc, Astellas, Kissei Pharmaceutical, Merck & Co., Sanofi, Hainan Selike Pharmaceutical Co., Ltd., Hunan Shentaichun Pharmaceutical Co., Ltd. and China Resources Saike Pharmaceutical Co., Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Benign Prostatic Hypertrophy Medication market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Benign Prostatic Hypertrophy Medication and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Benign Prostatic Hypertrophy Medication sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Benign Prostatic Hypertrophy Medication market size, projected growth trends, production technologies, key applications, and end-use industries.
Benign Prostatic Hypertrophy Medication Segment by Company
Abbott Laboratories
Allergan, Inc
Astellas
Kissei Pharmaceutical
Merck & Co.
Sanofi
Hainan Selike Pharmaceutical Co., Ltd.
Hunan Shentaichun Pharmaceutical Co., Ltd.
China Resources Saike Pharmaceutical Co., Ltd.
Jiangsu Lianhuan Pharmaceutical Co., Ltd.
Jiangsu Yongan Pharmaceutical Co., Ltd.
Kunming Jida Pharmaceutical Co., Ltd.
Lunan Beite Pharmaceutical Co., Ltd.
Nanjing Meirui Pharmaceutical Co., Ltd.
Shandong Langnuo Pharmaceutical Co., Ltd.
Shanghai Modern Pharmaceutical Co., Ltd.
Shanghai Abbott Pharmaceutical Co., Ltd.
Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd.
Suzhou Dongrui Pharmaceutical Co., Ltd.
Zhejiang Huahai Pharmaceutical Co., Ltd.
Zhongshan Kekekang Pharmaceutical Co., Ltd.
Benign Prostatic Hypertrophy Medication Segment by Type
Terazosin
Tamsulosin
Silodosin
Prusatide
Finasteride
Aprilite
Alfuzosin
Benign Prostatic Hypertrophy Medication Segment by Application
Hospital
Clinic
Other
Benign Prostatic Hypertrophy Medication Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Benign Prostatic Hypertrophy Medication market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Benign Prostatic Hypertrophy Medication and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Benign Prostatic Hypertrophy Medication.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Benign Prostatic Hypertrophy Medication market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Benign Prostatic Hypertrophy Medication manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Benign Prostatic Hypertrophy Medication in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Benign Prostatic Hypertrophy Medication in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
List of Tables
Table 1. Benign Prostatic Hypertrophy Medication Industry Trends
Table 2. Benign Prostatic Hypertrophy Medication Industry Drivers
Table 3. Benign Prostatic Hypertrophy Medication Industry Opportunities and Challenges
Table 4. Benign Prostatic Hypertrophy Medication Industry Restraints
Table 5. Global Benign Prostatic Hypertrophy Medication Revenue by Manufacturers (US$ Million) & (2021-2026)
Table 6. Global Benign Prostatic Hypertrophy Medication Revenue Market Share by Manufacturers (2021-2026)
Table 7. Global Benign Prostatic Hypertrophy Medication Sales by Manufacturers (K Units) & (2021-2026)
Table 8. Global Benign Prostatic Hypertrophy Medication Sales Market Share by Manufacturers
Table 9. Global Benign Prostatic Hypertrophy Medication Average Sales Price (US$/Unit) of Manufacturers (2021-2026)
Table 10. Global Benign Prostatic Hypertrophy Medication Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
Table 11. Global Benign Prostatic Hypertrophy Medication Key Manufacturers Manufacturing Sites & Headquarters
Table 12. Global Benign Prostatic Hypertrophy Medication Manufacturers, Product Type & Application
Table 13. Global Benign Prostatic Hypertrophy Medication Manufacturers Establishment Date
Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Global Benign Prostatic Hypertrophy Medication by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025)
Table 16. Major Manufacturers of Terazosin
Table 17. Major Manufacturers of Tamsulosin
Table 18. Major Manufacturers of Silodosin
Table 19. Major Manufacturers of Prusatide
Table 20. Major Manufacturers of Finasteride
Table 21. Major Manufacturers of Aprilite
Table 22. Major Manufacturers of Alfuzosin
Table 23. Global Benign Prostatic Hypertrophy Medication Sales by Type 2021 VS 2025 VS 2032 (K Units)
Table 24. Global Benign Prostatic Hypertrophy Medication Sales by Type (2021-2026) & (K Units)
Table 25. Global Benign Prostatic Hypertrophy Medication Sales by Type (2027-2032) & (K Units)
Table 26. Global Benign Prostatic Hypertrophy Medication Sales Market Share by Type (2021-2026)
Table 27. Global Benign Prostatic Hypertrophy Medication Sales Market Share by Type (2027-2032)
Table 28. Global Benign Prostatic Hypertrophy Medication Revenue by Type 2021 VS 2025 VS 2032 (K Units)
Table 29. Global Benign Prostatic Hypertrophy Medication Revenue by Type (2021-2026) & (K Units)
Table 30. Global Benign Prostatic Hypertrophy Medication Revenue by Type (2027-2032) & (K Units)
Table 31. Global Benign Prostatic Hypertrophy Medication Revenue Market Share by Type (2021-2026)
Table 32. Global Benign Prostatic Hypertrophy Medication Revenue Market Share by Type (2027-2032)
Table 33. Major Manufacturers of Hospital
Table 34. Major Manufacturers of Clinic
Table 35. Major Manufacturers of Other
Table 36. Global Benign Prostatic Hypertrophy Medication Sales by Application 2021 VS 2025 VS 2032 (K Units)
Table 37. Global Benign Prostatic Hypertrophy Medication Sales by Application (2021-2026) & (K Units)
Table 38. Global Benign Prostatic Hypertrophy Medication Sales by Application (2027-2032) & (K Units)
Table 39. Global Benign Prostatic Hypertrophy Medication Sales Market Share by Application (2021-2026)
Table 40. Global Benign Prostatic Hypertrophy Medication Sales Market Share by Application (2027-2032)
Table 41. Global Benign Prostatic Hypertrophy Medication Revenue by Application 2021 VS 2025 VS 2032 (K Units)
Table 42. Global Benign Prostatic Hypertrophy Medication Revenue by Application (2021-2026) & (K Units)
Table 43. Global Benign Prostatic Hypertrophy Medication Revenue by Application (2027-2032) & (K Units)
Table 44. Global Benign Prostatic Hypertrophy Medication Revenue Market Share by Application (2021-2026)
Table 45. Global Benign Prostatic Hypertrophy Medication Revenue Market Share by Application (2027-2032)
Table 46. Global Benign Prostatic Hypertrophy Medication Sales by Region: 2021 VS 2025 VS 2032 (K Units)
Table 47. Global Benign Prostatic Hypertrophy Medication Sales by Region (2021-2026) & (K Units)
Table 48. Global Benign Prostatic Hypertrophy Medication Sales Market Share by Region (2021-2026)
Table 49. Global Benign Prostatic Hypertrophy Medication Sales Forecasted by Region (2027-2032) & (K Units)
Table 50. Global Benign Prostatic Hypertrophy Medication Sales Forecasted Market Share by Region (2027-2032)
Table 51. North America Benign Prostatic Hypertrophy Medication Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units)
Table 52. North America Benign Prostatic Hypertrophy Medication Sales by Country (2021-2026) & (K Units)
Table 53. North America Benign Prostatic Hypertrophy Medication Sales by Country (2027-2032) & (K Units)
Table 54. Europe Benign Prostatic Hypertrophy Medication Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units)
Table 55. Europe Benign Prostatic Hypertrophy Medication Sales by Country (2021-2026) & (K Units)
Table 56. Europe Benign Prostatic Hypertrophy Medication Sales by Country (2027-2032) & (K Units)
Table 57. Asia Pacific Benign Prostatic Hypertrophy Medication Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units)
Table 58. Asia Pacific Benign Prostatic Hypertrophy Medication Sales by Country (2021-2026) & (K Units)
Table 59. Asia Pacific Benign Prostatic Hypertrophy Medication Sales by Country (2027-2032) & (K Units)
Table 60. South America, Middle East and Africa Benign Prostatic Hypertrophy Medication Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units)
Table 61. South America, Middle East and Africa Benign Prostatic Hypertrophy Medication Sales by Country (2021-2026) & (K Units)
Table 62. South America, Middle East and Africa Benign Prostatic Hypertrophy Medication Sales by Country (2027-2032) & (K Units)
Table 63. Global Benign Prostatic Hypertrophy Medication Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million)
Table 64. Global Benign Prostatic Hypertrophy Medication Revenue by Region (2021-2026) & (US$ Million)
Table 65. Global Benign Prostatic Hypertrophy Medication Revenue by Region (2027-2032) & (US$ Million)
Table 66. Global Benign Prostatic Hypertrophy Medication Revenue Market Share by Region (2021-2026)
Table 67. Global Benign Prostatic Hypertrophy Medication Revenue Market Share by Region (2027-2032)
Table 68. Abbott Laboratories Company Information
Table 69. Abbott Laboratories Business Overview
Table 70. Abbott Laboratories Benign Prostatic Hypertrophy Medication Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 71. Abbott Laboratories Benign Prostatic Hypertrophy Medication Product Portfolio
Table 72. Abbott Laboratories Recent Development
Table 73. Allergan, Inc Company Information
Table 74. Allergan, Inc Business Overview
Table 75. Allergan, Inc Benign Prostatic Hypertrophy Medication Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 76. Allergan, Inc Benign Prostatic Hypertrophy Medication Product Portfolio
Table 77. Allergan, Inc Recent Development
Table 78. Astellas Company Information
Table 79. Astellas Business Overview
Table 80. Astellas Benign Prostatic Hypertrophy Medication Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 81. Astellas Benign Prostatic Hypertrophy Medication Product Portfolio
Table 82. Astellas Recent Development
Table 83. Kissei Pharmaceutical Company Information
Table 84. Kissei Pharmaceutical Business Overview
Table 85. Kissei Pharmaceutical Benign Prostatic Hypertrophy Medication Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 86. Kissei Pharmaceutical Benign Prostatic Hypertrophy Medication Product Portfolio
Table 87. Kissei Pharmaceutical Recent Development
Table 88. Merck & Co. Company Information
Table 89. Merck & Co. Business Overview
Table 90. Merck & Co. Benign Prostatic Hypertrophy Medication Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 91. Merck & Co. Benign Prostatic Hypertrophy Medication Product Portfolio
Table 92. Merck & Co. Recent Development
Table 93. Sanofi Company Information
Table 94. Sanofi Business Overview
Table 95. Sanofi Benign Prostatic Hypertrophy Medication Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 96. Sanofi Benign Prostatic Hypertrophy Medication Product Portfolio
Table 97. Sanofi Recent Development
Table 98. Hainan Selike Pharmaceutical Co., Ltd. Company Information
Table 99. Hainan Selike Pharmaceutical Co., Ltd. Business Overview
Table 100. Hainan Selike Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 101. Hainan Selike Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
Table 102. Hainan Selike Pharmaceutical Co., Ltd. Recent Development
Table 103. Hunan Shentaichun Pharmaceutical Co., Ltd. Company Information
Table 104. Hunan Shentaichun Pharmaceutical Co., Ltd. Business Overview
Table 105. Hunan Shentaichun Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 106. Hunan Shentaichun Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
Table 107. Hunan Shentaichun Pharmaceutical Co., Ltd. Recent Development
Table 108. China Resources Saike Pharmaceutical Co., Ltd. Company Information
Table 109. China Resources Saike Pharmaceutical Co., Ltd. Business Overview
Table 110. China Resources Saike Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 111. China Resources Saike Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
Table 112. China Resources Saike Pharmaceutical Co., Ltd. Recent Development
Table 113. Jiangsu Lianhuan Pharmaceutical Co., Ltd. Company Information
Table 114. Jiangsu Lianhuan Pharmaceutical Co., Ltd. Business Overview
Table 115. Jiangsu Lianhuan Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 116. Jiangsu Lianhuan Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
Table 117. Jiangsu Lianhuan Pharmaceutical Co., Ltd. Recent Development
Table 118. Jiangsu Yongan Pharmaceutical Co., Ltd. Company Information
Table 119. Jiangsu Yongan Pharmaceutical Co., Ltd. Business Overview
Table 120. Jiangsu Yongan Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 121. Jiangsu Yongan Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
Table 122. Jiangsu Yongan Pharmaceutical Co., Ltd. Recent Development
Table 123. Kunming Jida Pharmaceutical Co., Ltd. Company Information
Table 124. Kunming Jida Pharmaceutical Co., Ltd. Business Overview
Table 125. Kunming Jida Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 126. Kunming Jida Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
Table 127. Kunming Jida Pharmaceutical Co., Ltd. Recent Development
Table 128. Lunan Beite Pharmaceutical Co., Ltd. Company Information
Table 129. Lunan Beite Pharmaceutical Co., Ltd. Business Overview
Table 130. Lunan Beite Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 131. Lunan Beite Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
Table 132. Lunan Beite Pharmaceutical Co., Ltd. Recent Development
Table 133. Nanjing Meirui Pharmaceutical Co., Ltd. Company Information
Table 134. Nanjing Meirui Pharmaceutical Co., Ltd. Business Overview
Table 135. Nanjing Meirui Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 136. Nanjing Meirui Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
Table 137. Nanjing Meirui Pharmaceutical Co., Ltd. Recent Development
Table 138. Shandong Langnuo Pharmaceutical Co., Ltd. Company Information
Table 139. Shandong Langnuo Pharmaceutical Co., Ltd. Business Overview
Table 140. Shandong Langnuo Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 141. Shandong Langnuo Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
Table 142. Shandong Langnuo Pharmaceutical Co., Ltd. Recent Development
Table 143. Shanghai Modern Pharmaceutical Co., Ltd. Company Information
Table 144. Shanghai Modern Pharmaceutical Co., Ltd. Business Overview
Table 145. Shanghai Modern Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 146. Shanghai Modern Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
Table 147. Shanghai Modern Pharmaceutical Co., Ltd. Recent Development
Table 148. Shanghai Abbott Pharmaceutical Co., Ltd. Company Information
Table 149. Shanghai Abbott Pharmaceutical Co., Ltd. Business Overview
Table 150. Shanghai Abbott Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 151. Shanghai Abbott Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
Table 152. Shanghai Abbott Pharmaceutical Co., Ltd. Recent Development
Table 153. Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Company Information
Table 154. Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Business Overview
Table 155. Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 156. Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
Table 157. Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Recent Development
Table 158. Suzhou Dongrui Pharmaceutical Co., Ltd. Company Information
Table 159. Suzhou Dongrui Pharmaceutical Co., Ltd. Business Overview
Table 160. Suzhou Dongrui Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 161. Suzhou Dongrui Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
Table 162. Suzhou Dongrui Pharmaceutical Co., Ltd. Recent Development
Table 163. Zhejiang Huahai Pharmaceutical Co., Ltd. Company Information
Table 164. Zhejiang Huahai Pharmaceutical Co., Ltd. Business Overview
Table 165. Zhejiang Huahai Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 166. Zhejiang Huahai Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
Table 167. Zhejiang Huahai Pharmaceutical Co., Ltd. Recent Development
Table 168. Zhongshan Kekekang Pharmaceutical Co., Ltd. Company Information
Table 169. Zhongshan Kekekang Pharmaceutical Co., Ltd. Business Overview
Table 170. Zhongshan Kekekang Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 171. Zhongshan Kekekang Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
Table 172. Zhongshan Kekekang Pharmaceutical Co., Ltd. Recent Development
Table 173. Key Raw Materials
Table 174. Raw Materials Key Suppliers
Table 175. Benign Prostatic Hypertrophy Medication Distributors List
Table 176. Benign Prostatic Hypertrophy Medication Customers List
Table 177. Research Programs/Design for This Report
Table 178. Authors List of This Report
Table 179. Secondary Sources
Table 180. Primary Sources
List of Figures
Figure 1. Benign Prostatic Hypertrophy Medication Product Image
Figure 2. Global Benign Prostatic Hypertrophy Medication Market Size (US$ Million), 2021 VS 2025 VS 2032
Figure 3. Global Benign Prostatic Hypertrophy Medication Market Size (2021-2032) & (US$ Million)
Figure 4. Global Benign Prostatic Hypertrophy Medication Sales (2021-2032) & (K Units)
Figure 5. Global Benign Prostatic Hypertrophy Medication Average Price (US$/Unit) & (2021-2032)
Figure 6. Global Top 5 and 10 Benign Prostatic Hypertrophy Medication Players Market Share by Revenue in 2025
Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 8. Terazosin Image
Figure 9. Tamsulosin Image
Figure 10. Silodosin Image
Figure 11. Prusatide Image
Figure 12. Finasteride Image
Figure 13. Aprilite Image
Figure 14. Alfuzosin Image
Figure 15. Global Benign Prostatic Hypertrophy Medication Sales by Type (2021 VS 2025 VS 2032) & (K Units)
Figure 16. Global Benign Prostatic Hypertrophy Medication Sales Market Share 2021 VS 2025 VS 2032
Figure 17. Global Benign Prostatic Hypertrophy Medication Sales Market Share by Type (2021-2032)
Figure 18. Global Benign Prostatic Hypertrophy Medication Revenue by Type (2021 VS 2025 VS 2032) & (K Units)
Figure 19. Global Benign Prostatic Hypertrophy Medication Revenue Market Share 2021 VS 2025 VS 2032
Figure 20. Global Benign Prostatic Hypertrophy Medication Revenue Market Share by Type (2021-2032)
Figure 21. Hospital Image
Figure 22. Clinic Image
Figure 23. Other Image
Figure 24. Global Benign Prostatic Hypertrophy Medication Sales by Application (2021 VS 2025 VS 2032) & (K Units)
Figure 25. Global Benign Prostatic Hypertrophy Medication Sales Market Share 2021 VS 2025 VS 2032
Figure 26. Global Benign Prostatic Hypertrophy Medication Sales Market Share by Application (2021-2032)
Figure 27. Global Benign Prostatic Hypertrophy Medication Revenue by Application (2021 VS 2025 VS 2032) & (K Units)
Figure 28. Global Benign Prostatic Hypertrophy Medication Revenue Market Share 2021 VS 2025 VS 2032
Figure 29. Global Benign Prostatic Hypertrophy Medication Revenue Market Share by Application (2021-2032)
Figure 30. North America Benign Prostatic Hypertrophy Medication Sales and Growth Rate (2021-2032) & (K Units)
Figure 31. North America Benign Prostatic Hypertrophy Medication Sales Market Share by Country (2021-2032)
Figure 32. U.S. Benign Prostatic Hypertrophy Medication Sales and Growth Rate (2021-2032) & (K Units)
Figure 33. Canada Benign Prostatic Hypertrophy Medication Sales and Growth Rate (2021-2032) & (K Units)
Figure 34. Mexico Benign Prostatic Hypertrophy Medication Sales and Growth Rate (2021-2032) & (K Units)
Figure 35. Europe Benign Prostatic Hypertrophy Medication Sales and Growth Rate (2021-2032) & (K Units)
Figure 36. Europe Benign Prostatic Hypertrophy Medication Sales Market Share by Country (2021-2032)
Figure 37. Germany Benign Prostatic Hypertrophy Medication Sales and Growth Rate (2021-2032) & (K Units)
Figure 38. France Benign Prostatic Hypertrophy Medication Sales and Growth Rate (2021-2032) & (K Units)
Figure 39. U.K. Benign Prostatic Hypertrophy Medication Sales and Growth Rate (2021-2032) & (K Units)
Figure 40. Italy Benign Prostatic Hypertrophy Medication Sales and Growth Rate (2021-2032) & (K Units)
Figure 41. Netherlands Benign Prostatic Hypertrophy Medication Sales and Growth Rate (2021-2032) & (K Units)
Figure 42. Asia Pacific Benign Prostatic Hypertrophy Medication Sales and Growth Rate (2021-2032) & (K Units)
Figure 43. Asia Pacific Benign Prostatic Hypertrophy Medication Sales Market Share by Country (2021-2032)
Figure 44. China Benign Prostatic Hypertrophy Medication Sales and Growth Rate (2021-2032) & (K Units)
Figure 45. Japan Benign Prostatic Hypertrophy Medication Sales and Growth Rate (2021-2032) & (K Units)
Figure 46. South Korea Benign Prostatic Hypertrophy Medication Sales and Growth Rate (2021-2032) & (K Units)
Figure 47. Southeast Asia Benign Prostatic Hypertrophy Medication Sales and Growth Rate (2021-2032) & (K Units)
Figure 48. India Benign Prostatic Hypertrophy Medication Sales and Growth Rate (2021-2032) & (K Units)
Figure 49. Australia Benign Prostatic Hypertrophy Medication Sales and Growth Rate (2021-2032) & (K Units)
Figure 50. South America, Middle East and Africa Benign Prostatic Hypertrophy Medication Sales and Growth Rate (2021-2032) & (K Units)
Figure 51. South America, Middle East and Africa Benign Prostatic Hypertrophy Medication Sales Market Share by Country (2021-2032)
Figure 52. Brazil Benign Prostatic Hypertrophy Medication Sales and Growth Rate (2021-2032) & (K Units)
Figure 53. South Africa Benign Prostatic Hypertrophy Medication Sales and Growth Rate (2021-2032) & (K Units)
Figure 54. Saudi Arabia Benign Prostatic Hypertrophy Medication Sales and Growth Rate (2021-2032) & (K Units)
Figure 55. Turkey Benign Prostatic Hypertrophy Medication Sales and Growth Rate (2021-2032) & (K Units)
Figure 56. Argentina Benign Prostatic Hypertrophy Medication Sales and Growth Rate (2021-2032) & (K Units)
Figure 57. UAE Benign Prostatic Hypertrophy Medication Sales and Growth Rate (2021-2032) & (K Units)
Figure 58. Egypt Benign Prostatic Hypertrophy Medication Sales and Growth Rate (2021-2032) & (K Units)
Figure 59. Chile Benign Prostatic Hypertrophy Medication Sales and Growth Rate (2021-2032) & (K Units)
Figure 60. Global Benign Prostatic Hypertrophy Medication Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million)
Figure 61. Global Benign Prostatic Hypertrophy Medication Revenue Market Share by Region in Percentage: 2025 Versus 2032
Figure 62. North America Benign Prostatic Hypertrophy Medication Revenue (2021-2032) & (US$ Million)
Figure 63. North America Benign Prostatic Hypertrophy Medication Revenue Share by Country: 2021 VS 2025 VS 2032
Figure 64. Europe Benign Prostatic Hypertrophy Medication Revenue (2021-2032) & (US$ Million)
Figure 65. Europe Benign Prostatic Hypertrophy Medication Revenue Share by Country: 2021 VS 2025 VS 2032
Figure 66. Asia-Pacific Benign Prostatic Hypertrophy Medication Revenue (2021-2032) & (US$ Million)
Figure 67. Asia-Pacific Benign Prostatic Hypertrophy Medication Revenue Share by Country: 2021 VS 2025 VS 2032
Figure 68. South America, Middle East and Africa Benign Prostatic Hypertrophy Medication Revenue (2021-2032) & (US$ Million)
Figure 69. South America, Middle East and Africa Benign Prostatic Hypertrophy Medication Revenue Share by Country: 2021 VS 2025 VS 2032
Figure 70. Benign Prostatic Hypertrophy Medication Value Chain
Figure 71. Manufacturing Cost Structure
Figure 72. Benign Prostatic Hypertrophy Medication Production Mode & Process
Figure 73. Direct Comparison with Distribution Share
Figure 74. Distributors Profiles
Figure 75. Years Considered
Figure 76. Research Process
Figure 77. Key Executives Interviewed
Scope & coverage.
Types
- Terazosin
- Tamsulosin
- Silodosin
- Prusatide
- Finasteride
- Aprilite
- Alfuzosin
Applications
- Hospital
- Clinic
- Other
Companies covered
- Abbott Laboratories
- Allergan, Inc
- Astellas
- Kissei Pharmaceutical
- Merck & Co.
- Sanofi
- Hainan Selike Pharmaceutical Co., Ltd.
- Hunan Shentaichun Pharmaceutical Co., Ltd.
- China Resources Saike Pharmaceutical Co., Ltd.
- Jiangsu Lianhuan Pharmaceutical Co., Ltd.
- Jiangsu Yongan Pharmaceutical Co., Ltd.
- Kunming Jida Pharmaceutical Co., Ltd.
- Lunan Beite Pharmaceutical Co., Ltd.
- Nanjing Meirui Pharmaceutical Co., Ltd.
- Shandong Langnuo Pharmaceutical Co., Ltd.
- Shanghai Modern Pharmaceutical Co., Ltd.
- Shanghai Abbott Pharmaceutical Co., Ltd.
- Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd.
- Suzhou Dongrui Pharmaceutical Co., Ltd.
- Zhejiang Huahai Pharmaceutical Co., Ltd.
- Zhongshan Kekekang Pharmaceutical Co., Ltd.
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Benign Prostatic Hypertrophy Medication Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Benign Prostatic Hypertrophy Medication Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Benign Prostatic Hypertrophy Medication Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Benign Prostatic Hypertrophy Medication Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Benign Prostatic Hypertrophy Medication Market Dynamics
- 2.1 Benign Prostatic Hypertrophy Medication Industry Trends
- 2.2 Benign Prostatic Hypertrophy Medication Industry Drivers
- 2.3 Benign Prostatic Hypertrophy Medication Industry Opportunities and Challenges
- 2.4 Benign Prostatic Hypertrophy Medication Industry Restraints
3 Benign Prostatic Hypertrophy Medication Market by Manufacturers
- 3.1 Global Benign Prostatic Hypertrophy Medication Revenue by Manufacturers (2021-2026)
- 3.2 Global Benign Prostatic Hypertrophy Medication Sales by Manufacturers (2021-2026)
- 3.3 Global Benign Prostatic Hypertrophy Medication Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Benign Prostatic Hypertrophy Medication Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Benign Prostatic Hypertrophy Medication Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Benign Prostatic Hypertrophy Medication Manufacturers, Product Type & Application
- 3.7 Global Benign Prostatic Hypertrophy Medication Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Benign Prostatic Hypertrophy Medication Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Benign Prostatic Hypertrophy Medication Players Market Share by Revenue in 2025
- 3.8.3 2025 Benign Prostatic Hypertrophy Medication Tier 1, Tier 2, and Tier 3
4 Benign Prostatic Hypertrophy Medication Market by Type
- 4.1 Benign Prostatic Hypertrophy Medication Type Introduction
- 4.1.1 Terazosin
- 4.1.2 Tamsulosin
- 4.1.3 Silodosin
- 4.1.4 Prusatide
- 4.1.5 Finasteride
- 4.1.6 Aprilite
- 4.1.7 Alfuzosin
- 4.2 Global Benign Prostatic Hypertrophy Medication Sales by Type
- 4.2.1 Global Benign Prostatic Hypertrophy Medication Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Benign Prostatic Hypertrophy Medication Sales by Type (2021-2032)
- 4.2.3 Global Benign Prostatic Hypertrophy Medication Sales Market Share by Type (2021-2032)
- 4.3 Global Benign Prostatic Hypertrophy Medication Revenue by Type
- 4.3.1 Global Benign Prostatic Hypertrophy Medication Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Benign Prostatic Hypertrophy Medication Revenue by Type (2021-2032)
- 4.3.3 Global Benign Prostatic Hypertrophy Medication Revenue Market Share by Type (2021-2032)
5 Benign Prostatic Hypertrophy Medication Market by Application
- 5.1 Benign Prostatic Hypertrophy Medication Application Introduction
- 5.1.1 Hospital
- 5.1.2 Clinic
- 5.1.3 Other
- 5.2 Global Benign Prostatic Hypertrophy Medication Sales by Application
- 5.2.1 Global Benign Prostatic Hypertrophy Medication Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Benign Prostatic Hypertrophy Medication Sales by Application (2021-2032)
- 5.2.3 Global Benign Prostatic Hypertrophy Medication Sales Market Share by Application (2021-2032)
- 5.3 Global Benign Prostatic Hypertrophy Medication Revenue by Application
- 5.3.1 Global Benign Prostatic Hypertrophy Medication Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Benign Prostatic Hypertrophy Medication Revenue by Application (2021-2032)
- 5.3.3 Global Benign Prostatic Hypertrophy Medication Revenue Market Share by Application (2021-2032)
6 Global Benign Prostatic Hypertrophy Medication Sales by Region
- 6.1 Global Benign Prostatic Hypertrophy Medication Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Benign Prostatic Hypertrophy Medication Sales by Region (2021-2032)
- 6.2.1 Global Benign Prostatic Hypertrophy Medication Sales by Region (2021-2026)
- 6.2.2 Global Benign Prostatic Hypertrophy Medication Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Benign Prostatic Hypertrophy Medication Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Benign Prostatic Hypertrophy Medication Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Benign Prostatic Hypertrophy Medication Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Benign Prostatic Hypertrophy Medication Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Benign Prostatic Hypertrophy Medication Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Benign Prostatic Hypertrophy Medication Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Benign Prostatic Hypertrophy Medication Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Benign Prostatic Hypertrophy Medication Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Benign Prostatic Hypertrophy Medication Revenue by Region
- 7.1 Global Benign Prostatic Hypertrophy Medication Revenue by Region
- 7.1.1 Global Benign Prostatic Hypertrophy Medication Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Benign Prostatic Hypertrophy Medication Revenue by Region (2021-2026)
- 7.1.3 Global Benign Prostatic Hypertrophy Medication Revenue by Region (2027-2032)
- 7.1.4 Global Benign Prostatic Hypertrophy Medication Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Benign Prostatic Hypertrophy Medication Revenue (2021-2032)
- 7.2.2 North America Benign Prostatic Hypertrophy Medication Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Benign Prostatic Hypertrophy Medication Revenue (2021-2032)
- 7.3.2 Europe Benign Prostatic Hypertrophy Medication Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Benign Prostatic Hypertrophy Medication Revenue (2021-2032)
- 7.4.2 Asia-Pacific Benign Prostatic Hypertrophy Medication Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Benign Prostatic Hypertrophy Medication Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Benign Prostatic Hypertrophy Medication Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Abbott Laboratories
- 8.1.1 Abbott Laboratories Company Information
- 8.1.2 Abbott Laboratories Business Overview
- 8.1.3 Abbott Laboratories Benign Prostatic Hypertrophy Medication Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Abbott Laboratories Benign Prostatic Hypertrophy Medication Product Portfolio
- 8.1.5 Abbott Laboratories Recent Developments
- 8.2 Allergan, Inc
- 8.2.1 Allergan, Inc Company Information
- 8.2.2 Allergan, Inc Business Overview
- 8.2.3 Allergan, Inc Benign Prostatic Hypertrophy Medication Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Allergan, Inc Benign Prostatic Hypertrophy Medication Product Portfolio
- 8.2.5 Allergan, Inc Recent Developments
- 8.3 Astellas
- 8.3.1 Astellas Company Information
- 8.3.2 Astellas Business Overview
- 8.3.3 Astellas Benign Prostatic Hypertrophy Medication Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Astellas Benign Prostatic Hypertrophy Medication Product Portfolio
- 8.3.5 Astellas Recent Developments
- 8.4 Kissei Pharmaceutical
- 8.4.1 Kissei Pharmaceutical Company Information
- 8.4.2 Kissei Pharmaceutical Business Overview
- 8.4.3 Kissei Pharmaceutical Benign Prostatic Hypertrophy Medication Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Kissei Pharmaceutical Benign Prostatic Hypertrophy Medication Product Portfolio
- 8.4.5 Kissei Pharmaceutical Recent Developments
- 8.5 Merck & Co.
- 8.5.1 Merck & Co. Company Information
- 8.5.2 Merck & Co. Business Overview
- 8.5.3 Merck & Co. Benign Prostatic Hypertrophy Medication Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Merck & Co. Benign Prostatic Hypertrophy Medication Product Portfolio
- 8.5.5 Merck & Co. Recent Developments
- 8.6 Sanofi
- 8.6.1 Sanofi Company Information
- 8.6.2 Sanofi Business Overview
- 8.6.3 Sanofi Benign Prostatic Hypertrophy Medication Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Sanofi Benign Prostatic Hypertrophy Medication Product Portfolio
- 8.6.5 Sanofi Recent Developments
- 8.7 Hainan Selike Pharmaceutical Co., Ltd.
- 8.7.1 Hainan Selike Pharmaceutical Co., Ltd. Company Information
- 8.7.2 Hainan Selike Pharmaceutical Co., Ltd. Business Overview
- 8.7.3 Hainan Selike Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Hainan Selike Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
- 8.7.5 Hainan Selike Pharmaceutical Co., Ltd. Recent Developments
- 8.8 Hunan Shentaichun Pharmaceutical Co., Ltd.
- 8.8.1 Hunan Shentaichun Pharmaceutical Co., Ltd. Company Information
- 8.8.2 Hunan Shentaichun Pharmaceutical Co., Ltd. Business Overview
- 8.8.3 Hunan Shentaichun Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Hunan Shentaichun Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
- 8.8.5 Hunan Shentaichun Pharmaceutical Co., Ltd. Recent Developments
- 8.9 China Resources Saike Pharmaceutical Co., Ltd.
- 8.9.1 China Resources Saike Pharmaceutical Co., Ltd. Company Information
- 8.9.2 China Resources Saike Pharmaceutical Co., Ltd. Business Overview
- 8.9.3 China Resources Saike Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 China Resources Saike Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
- 8.9.5 China Resources Saike Pharmaceutical Co., Ltd. Recent Developments
- 8.10 Jiangsu Lianhuan Pharmaceutical Co., Ltd.
- 8.10.1 Jiangsu Lianhuan Pharmaceutical Co., Ltd. Company Information
- 8.10.2 Jiangsu Lianhuan Pharmaceutical Co., Ltd. Business Overview
- 8.10.3 Jiangsu Lianhuan Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 Jiangsu Lianhuan Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
- 8.10.5 Jiangsu Lianhuan Pharmaceutical Co., Ltd. Recent Developments
- 8.11 Jiangsu Yongan Pharmaceutical Co., Ltd.
- 8.11.1 Jiangsu Yongan Pharmaceutical Co., Ltd. Company Information
- 8.11.2 Jiangsu Yongan Pharmaceutical Co., Ltd. Business Overview
- 8.11.3 Jiangsu Yongan Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.11.4 Jiangsu Yongan Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
- 8.11.5 Jiangsu Yongan Pharmaceutical Co., Ltd. Recent Developments
- 8.12 Kunming Jida Pharmaceutical Co., Ltd.
- 8.12.1 Kunming Jida Pharmaceutical Co., Ltd. Company Information
- 8.12.2 Kunming Jida Pharmaceutical Co., Ltd. Business Overview
- 8.12.3 Kunming Jida Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.12.4 Kunming Jida Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
- 8.12.5 Kunming Jida Pharmaceutical Co., Ltd. Recent Developments
- 8.13 Lunan Beite Pharmaceutical Co., Ltd.
- 8.13.1 Lunan Beite Pharmaceutical Co., Ltd. Company Information
- 8.13.2 Lunan Beite Pharmaceutical Co., Ltd. Business Overview
- 8.13.3 Lunan Beite Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.13.4 Lunan Beite Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
- 8.13.5 Lunan Beite Pharmaceutical Co., Ltd. Recent Developments
- 8.14 Nanjing Meirui Pharmaceutical Co., Ltd.
- 8.14.1 Nanjing Meirui Pharmaceutical Co., Ltd. Company Information
- 8.14.2 Nanjing Meirui Pharmaceutical Co., Ltd. Business Overview
- 8.14.3 Nanjing Meirui Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.14.4 Nanjing Meirui Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
- 8.14.5 Nanjing Meirui Pharmaceutical Co., Ltd. Recent Developments
- 8.15 Shandong Langnuo Pharmaceutical Co., Ltd.
- 8.15.1 Shandong Langnuo Pharmaceutical Co., Ltd. Company Information
- 8.15.2 Shandong Langnuo Pharmaceutical Co., Ltd. Business Overview
- 8.15.3 Shandong Langnuo Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.15.4 Shandong Langnuo Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
- 8.15.5 Shandong Langnuo Pharmaceutical Co., Ltd. Recent Developments
- 8.16 Shanghai Modern Pharmaceutical Co., Ltd.
- 8.16.1 Shanghai Modern Pharmaceutical Co., Ltd. Company Information
- 8.16.2 Shanghai Modern Pharmaceutical Co., Ltd. Business Overview
- 8.16.3 Shanghai Modern Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.16.4 Shanghai Modern Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
- 8.16.5 Shanghai Modern Pharmaceutical Co., Ltd. Recent Developments
- 8.17 Shanghai Abbott Pharmaceutical Co., Ltd.
- 8.17.1 Shanghai Abbott Pharmaceutical Co., Ltd. Company Information
- 8.17.2 Shanghai Abbott Pharmaceutical Co., Ltd. Business Overview
- 8.17.3 Shanghai Abbott Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.17.4 Shanghai Abbott Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
- 8.17.5 Shanghai Abbott Pharmaceutical Co., Ltd. Recent Developments
- 8.18 Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd.
- 8.18.1 Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Company Information
- 8.18.2 Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Business Overview
- 8.18.3 Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.18.4 Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
- 8.18.5 Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Recent Developments
- 8.19 Suzhou Dongrui Pharmaceutical Co., Ltd.
- 8.19.1 Suzhou Dongrui Pharmaceutical Co., Ltd. Company Information
- 8.19.2 Suzhou Dongrui Pharmaceutical Co., Ltd. Business Overview
- 8.19.3 Suzhou Dongrui Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.19.4 Suzhou Dongrui Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
- 8.19.5 Suzhou Dongrui Pharmaceutical Co., Ltd. Recent Developments
- 8.20 Zhejiang Huahai Pharmaceutical Co., Ltd.
- 8.20.1 Zhejiang Huahai Pharmaceutical Co., Ltd. Company Information
- 8.20.2 Zhejiang Huahai Pharmaceutical Co., Ltd. Business Overview
- 8.20.3 Zhejiang Huahai Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.20.4 Zhejiang Huahai Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
- 8.20.5 Zhejiang Huahai Pharmaceutical Co., Ltd. Recent Developments
- 8.21 Zhongshan Kekekang Pharmaceutical Co., Ltd.
- 8.21.1 Zhongshan Kekekang Pharmaceutical Co., Ltd. Company Information
- 8.21.2 Zhongshan Kekekang Pharmaceutical Co., Ltd. Business Overview
- 8.21.3 Zhongshan Kekekang Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.21.4 Zhongshan Kekekang Pharmaceutical Co., Ltd. Benign Prostatic Hypertrophy Medication Product Portfolio
- 8.21.5 Zhongshan Kekekang Pharmaceutical Co., Ltd. Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Benign Prostatic Hypertrophy Medication Value Chain Analysis
- 9.1.1 Benign Prostatic Hypertrophy Medication Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Benign Prostatic Hypertrophy Medication Production Mode & Process
- 9.2 Benign Prostatic Hypertrophy Medication Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Benign Prostatic Hypertrophy Medication Distributors
- 9.2.3 Benign Prostatic Hypertrophy Medication Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
$3,950USD
Buy nowPDF by email within 3–5 working days after payment confirmation.
Talk to an analyst